STOCK TITAN
  1. Home
  2. Sec-filings
  3. GMED
  4. [Form 4] GLOBUS MEDICAL INC Insider Trading Activity

GMED insider exercises options at $44.14, then sells 25,000 shares

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Globus Medical (GMED) reported an insider transaction by a director. On 11/11/2025, the director exercised stock options for 25,000 Class A shares at $44.14 and then sold 25,000 Class A shares at a $84.2903 weighted average price.

Following these transactions, the director held 0 shares directly. The options were granted on May 1, 2019, were fully vested, and had an expiration date of 05/01/2029.

Positive

  • None.

Negative

  • None.
Insider ZARRILLI STEPHEN T
Role Director
Sold 25,000 shs ($2.11M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy Class A Common Stock) 25,000 $0.00 --
Exercise Class A Common Stock 25,000 $44.14 $1.10M
Sale Class A Common Stock 25,000 $84.2903 $2.11M
Holdings After Transaction: Stock Option (Right to Buy Class A Common Stock) — 0 shares (Direct); Class A Common Stock — 25,000 shares (Direct)
Footnotes (1)
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.11 to $84.65, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. These options were granted on May 1, 2019 and are fully vested.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ZARRILLI STEPHEN T
(Last) (First) (Middle)
VALLEY FORGE BUSINESS CENTER
2560 GENERAL ARMISTEAD AVENUE
(Street)
AUDUBON PA 19403
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 11/11/2025 M 25,000 A $44.14 25,000 D
Class A Common Stock 11/11/2025 S 25,000 D $84.2903(1) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock) $44.14 11/11/2025 M 25,000 (2) 05/01/2029 Class A Common Stock 25,000 $0 0 D
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.11 to $84.65, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
2. These options were granted on May 1, 2019 and are fully vested.
/s/ Kelly G. Huller, Attorney-in-Fact 11/13/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did GMED disclose?

A director exercised options for 25,000 shares at $44.14 and sold 25,000 shares at a $84.2903 weighted average on 11/11/2025.

How many GMED shares were sold and at what price?

The director sold 25,000 Class A shares at a $84.2903 weighted average price.

How many GMED shares did the insider own after the transaction?

The director reported 0 shares directly owned after the sale.

What were the terms of the exercised options?

Stock options with an exercise price of $44.14 for 25,000 shares, granted on May 1, 2019, fully vested, expiring on 05/01/2029.

Were the sales executed in multiple trades?

Yes. The filing notes a weighted average price with individual trades ranging from $84.11 to $84.65.

What security class was involved in the GMED transactions?

The transactions involved Class A Common Stock of Globus Medical.